Law360, New York (November 14, 2003, 12:00 AM EST) -- The U.S. District Court for the District of Columbia has given cancer patients treated with Taxol (paclitaxel) another three months to file claims against Bristol-Myers Squibb for delaying generic competition by fraudulently obtaining patents, Idaho Attorney General Lawrence Wasden said in a statement.
Consumers who used Taxol between 1999 and February 2003 and their survivors now have until Jan. 31 to file a claim under a settlement agreement reached earlier this year.
The court has tentatively approved the settlement in the antitrust lawsuit filed by 29...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.